Rho激酶抑制剂与肺动脉高压

Rho kinase inhibitors and pulmonary arterial hypertension

肺动脉高压（PAH）是以肺动脉压力持续升高，进行性肺血管重塑为特征，最终导致严重右心功能衰竭甚至死亡的一种疾病。目前，PAH发病机制尚未完全明了，并且现有的治疗手段不能完全缓解症状，因此患者长期生存率仍较低。Rho／ROCK通路是与PAH发生、发展密切相关的信号通路之一，近年来已成为治疗PAH富有潜力的新靶点。本文主要综述了近年来Rho激酶抑制剂在肺动脉高压研究中的相关进展。

Pulmonary arterial hypertension（PAH）is featured as persistent elevation of pulmonary artery pressure, with a progressive pulmonary vascular remodeling, leading to severe right heart failure and premature death. The pathogenesis is not fully clear. Current available therapies cannot completely relief the symptoms of PAH.The ras homolog family member A （RhoA）-Rho kinase （ROCK） axis is one of the most important pathways involved in the development of PAH. Recently, Rho kinase inhibitors have gained much attention for its therapeutic potential in PAH. This review focused on the research progress of Rho kinase inhibitors in PAH.